P2RY12 and ST Elevation Myocardial Infarction: Cardiogenic shock (CS) is a serious complication of acute myocardial infarction (AMI) and remains an important cause of death with a rate of 30%–45%.1,2 While the question of pre-treatment with P2Y12 inhibitors has been well addressed in Non-ST Elevation Myocardial Infarction and ST Elevation Myocardial Infarction, there are currently sparse data in patients with AMI-CS.